Erudio Healtherudio.com
Sponsor
GSK trials: what clinicians said in public
HCP commentary reports on 4 clinical trials sponsored by GSK: BEHOLD-1, DREAMM-10, StrateGIST 3 and TOPACIO. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 20 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (GlaxoSmithKline; Sierra Oncology LLC - a GSK company; Tesaro, Inc.; IDRX, Inc., a wholly owned subsidiary of GSK, LLC). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| TOPACIO NCT02657889 · Tesaro, Inc. | advanced triple-negative breast cancer or recurrent ovarian cancer | Phase 1/Phase 2 | 183 | 30 | Standard | Nov 15, 2026 | Preview |
| BEHOLD-1 NCT06431594 · GlaxoSmithKline | advanced solid tumors | Phase 1 | 100 | 24 | Focused | Oct 31, 2026 | Preview |
| StrateGIST 3 NCT07218926 · GlaxoSmithKline | metastatic and/or unresectable gastrointestinal stromal tumors after imatinib | Phase 3 | 84 | 17 | Focused | Oct 31, 2026 | Preview |
| DREAMM-10 NCT06679101 · GlaxoSmithKline | transplant-ineligible, newly diagnosed multiple myeloma | Phase 3 | 406 | 41 | Deep | Oct 28, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DREAMM-7 NCT04246047 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| RUBY NCT03981796 · Tesaro, Inc. DeepView → | primary advanced or recurrent endometrial cancer | Phase 3 | Deep | View | |||
| DREAMM-8 NCT04484623 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| SIMPLIFY-1 NCT01969838 · Sierra Oncology LLC - a GSK company DeepView → | JAK inhibitor-naive myelofibrosis | Phase 3 | Deep | View | |||
| AZUR-1 NCT05723562 · GlaxoSmithKline DeepView → | untreated stage II/III dMMR/MSI-H locally advanced rectal cancer | Phase 2 | Deep | View | |||
| SIMPLIFY-2 NCT02101268 · Sierra Oncology LLC - a GSK company DeepView → | anemic or thrombocytopenic myelofibrosis previously treated with ruxolitinib | Phase 3 | Deep | View | |||
| DREAMM-3 NCT04162210 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 3 | Deep | View | |||
| DREAMM-9 NCT04091126 · GlaxoSmithKline DeepView → | newly diagnosed multiple myeloma | Phase 1 | Deep | View | |||
| ZEST NCT04915755 · GlaxoSmithKline DeepView → | HER2-negative BRCA-mutated or triple-negative breast cancer, molecular disease | Phase 3 | Deep | View | |||
| DREAMM-6 NCT03544281 · GlaxoSmithKline DeepView → | relapsed/refractory multiple myeloma | Phase 1/Phase 2 | Deep | View | |||
| DREAMM-1 NCT02064387 · GlaxoSmithKline StandardView → | relapsed or refractory multiple myeloma | Phase 1 | Standard | View | |||
| POPSTAR NCT06521567 · GlaxoSmithKline StandardView → | pediatric and young adult tumors | Phase 1/Phase 2 | Standard | View | |||
| INDUCE-1 NCT02723955 · GlaxoSmithKline FocusedView → | Not given | Phase 1 | Focused | View | |||
| ZEAL-1L NCT04475939 · GlaxoSmithKline FocusedView → | advanced or metastatic non-small cell lung cancer | Phase 3 | Focused | View | |||
| EMBOLD SCLC-301 NCT07099898 · GlaxoSmithKline FocusedView → | relapsed small cell lung cancer | Phase 3 | Focused | View | |||
| MOMENTUM NCT04173494 · Sierra Oncology LLC - a GSK company FocusedView → | symptomatic JAK inhibitor-experienced myelofibrosis with anemia | Phase 3 | Focused | View | |||
| NCT05489237 NCT05489237 · IDRX, Inc., a wholly owned subsidiary of GSK, LLC FocusedView → | metastatic and/or unresectable gastrointestinal stromal tumors | Phase 1 | Focused | View | |||
| JADE NCT06256588 · GlaxoSmithKline FocusedView → | locally advanced unresected HNSCC | Phase 3 | Focused | View | |||
| GALAXIES Lung-301 NCT06472076 · GlaxoSmithKline FocusedView → | previously untreated PD-L1 high non-small-cell lung cancer | Phase 3 | Focused | View | |||
| BEHOLD-Endometrial01 NCT07286331 · GlaxoSmithKline FocusedView → | endometrial cancer after platinum-based chemotherapy and immunotherapy | Phase 3 | Focused | View | |||